ArticleAmerican journal of translational research2025
Cerebrospinal fluid biomarkers for predicting immunotherapy response in autoimmune encephalitis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-omics integration in autoimmune encephalitis: from novel biomarker discovery to precision therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate the predictive value of cerebrospinal fluid (CSF) biomarkers for immunotherapy response in patients with autoimmune encephalitis (AE).
methodsWe conducted a retrospective analysis of 80 patients with AE who were hospitalized at Zhongshan Hospital of Xiamen University between January 2014 and July 2024. Treatment response was evaluated using a combined assessment of the modified Rankin Scale (mRS) and the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) scores. Patients were classified into good response (n = 52, 65.0%) and poor response (n = 28, 35.0%) groups according to predefined criteria. Feature selection was performed using the Boruta algorithm and least absolute shrinkage and selection operator regression, followed by multivariable logistic regression to identify independent predictors. Diagnostic performance was evaluated using receiver operating characteristic curves and area under the curve (AUC) analysis.
resultsFollowing systematic feature selection and multicollinearity assessment, three independent predictors of poor immunotherapy response were identified: intrathecal immunoglobulin G (IgG) synthesis rate (OR = 1.57, 95% CI: 1.03-2.45, P = 0.037), peak CASE score (OR = 1.22, 95% CI: 1.07-1.42, P = 0.004), and CSF albumin concentration (OR = 1.00, 95% CI: 1.00-1.01, P = 0.005). Among individual biomarkers, intrathecal IgG synthesis rate demonstrated the highest discriminatory ability (AUC = 0.734), followed by CSF albumin (AUC = 0.722). The combined predictive model showed significantly superior diagnostic performance compared to any single biomarker (AUC = 0.896).
conclusionsElevated intrathecal IgG synthesis, peak CASE score, and CSF albumin concentration are independent predictors of poor response in patients with AE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.